Literature DB >> 2292233

The clinical application of radiopharmaceuticals.

N E Leeds1.   

Abstract

This article highlights the choices and the arguments in the selection of appropriate contrast materials in radiological examinations--nonionic versus ionic contrast material--and aims to assist the physician in decision-making. Various authors have raised questions concerning the proposed advantages of nonionic contrast material. However, studies in low risk patients have shown more complications with the use of ionic contrast than nonionic contrast materials; this is the important group of patients since in high risk patients nonionics are used almost exclusively. The important factor that increases the controversy is cost, which is significant since nonionic agents cost 10 to 15 times more than ionic agents in the USA. Thus, cost-benefit considerations are important because price sensitivity and cost may determine fund availability for equipment or materials that also may be necessary or important in improving patient care. In magnetic resonance imaging (MRI), as in computed tomography (CT), the use of contrast material has improved diagnostic accuracy and the ability to reveal lesions not otherwise easily detected in brain and spinal cord imaging. These include separating scan from disc, meningitis, meningeal spread of tumour, tumour seeding, small metastases, intracanalicular tumours, separating major mass from oedema, determining bulk tumour size and ability to demonstrate blood vessels so dynamic circulatory changes may be revealed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2292233     DOI: 10.2165/00003495-199040050-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  30 in total

Review 1.  The R.A.C.R. survey of intravenous contrast media reactions. A preliminary report.

Authors:  F J Palmer
Journal:  Australas Radiol       Date:  1988-02

2.  Gadolinium-DTPA-enhanced MR imaging of the postoperative lumbar spine: time course and mechanism of enhancement.

Authors:  J S Ross; R Delamarter; M G Hueftle; T J Masaryk; M Aikawa; J Carter; C VanDyke; M T Modic
Journal:  AJR Am J Roentgenol       Date:  1989-04       Impact factor: 3.959

3.  Differing mechanisms of clotting inhibition by ionic and nonionic contrast agents.

Authors:  J J Ing; D C Smith; B S Bull
Journal:  Radiology       Date:  1989-08       Impact factor: 11.105

4.  Contrast agents and enzyme inhibition. II. Mechanisms.

Authors:  M J Howell; P Dawson
Journal:  Br J Radiol       Date:  1985-09       Impact factor: 3.039

5.  Iopamidol and metrizamide for myelography: prospective double-blind clinical trial.

Authors:  G Witwer; E D Cacayorin; A D Bernstein; M Y Hubballah; H A Yuan; S A Kieffer
Journal:  AJR Am J Roentgenol       Date:  1984-10       Impact factor: 3.959

6.  Contrast media and enzyme inhibition. I. Cholinesterase.

Authors:  P Dawson; D Edgerton
Journal:  Br J Radiol       Date:  1983-09       Impact factor: 3.039

7.  Contrast medium-induced adverse reactions: economic outcome.

Authors:  N R Powe; E P Steinberg; J E Erickson; R D Moore; C R Smith; R I White; J A Brinker; E K Fishman; S J Zinreich; M L Kinnison
Journal:  Radiology       Date:  1988-10       Impact factor: 11.105

8.  Tolerance of iohexol, iopamidol, and metrizamide in lumbar myelography.

Authors:  C M Elkin; A M Levan; N E Leeds
Journal:  Surg Neurol       Date:  1986-12

9.  Multicenter double-blind placebo-controlled study of gadopentetate dimeglumine as an MR contrast agent: evaluation in patients with cerebral lesions.

Authors:  E J Russell; T F Schaible; W Dillon; B Drayer; J LiPuma; A Mancuso; K Maravilla; H A Goldstein
Journal:  AJR Am J Roentgenol       Date:  1989-04       Impact factor: 3.959

Review 10.  Results of randomized controlled trials of low-versus high-osmolality contrast media.

Authors:  M L Kinnison; N R Powe; E P Steinberg
Journal:  Radiology       Date:  1989-02       Impact factor: 11.105

View more
  1 in total

Review 1.  The adverse effects of angiographic radiocontrast media.

Authors:  M Westhoff-Bleck; J S Bleck; S Jost
Journal:  Drug Saf       Date:  1991 Jan-Feb       Impact factor: 5.606

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.